Cancer Res Treat.  2003 Jun;35(3):239-244.

A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer

• Lee JA
• Lee KS
• Ahn JS
• Byun JH
• Song HH
• Zang DY
• Park YI
• Park YS
• Mo EK
• Kim DK
• Lee MG
• Hyun IG
• Jung KS
• Bang SM
• Park GY
• Park JW
• Cho EK
• Jeong SH
• Shin DB
• Lee JH

Abstract

PURPOSE
Paclitaxel and cisplatin, active drugs in the treatment of non-small-cell lung cancer (NSCLC), have been found to be synergistic and less myelotoxic in combination when the paclitaxel is given 24 hr prior to the cisplatin. Their antitumor activity and toxicity in patients with advanced NSCLC has been evaluated herein. MATERIALS AND METHODS: Seventy-four chemonaive patients, with advanced NSCLC, were enrolled. Paclitaxel, 175 mg/m2, was administered on day 1, followed 24 hr later by cisplatin, 75 mg/m2, on day 2. RESULTS: The overall response rate, median time to progression and median survival time were 51%, 7.1 months (95% confidence interval (CI), 5.5~8.7 months) and 13.7 months (95% CI, 11.3~16.1 months), respectively. There were significant differences in the overall survival rates in relation to stage and the ECOG performance status(PS). The toxicity was mainly nonhematological. Grade > or =3 neuropathy occurred in 2 (3%) patients, myalgia in 3 (4%), and bone pain in 3 (4%). The hematological toxicity was mild, and no grade 3 or 4 neutropenia was observed. CONCLUSION: The combination of paclitaxel and cisplatin is an effective and tolerable treatment regimen for advanced NSCLC during first line chemotherapy. The main toxicity was nonhematological, such as peripheral neuropathy, myalgia and bone pain, whereas the hematological toxicity itself was mild.

Keyword

Non-small-cell lung cancer; Paclitaxel; Cisplatin

MeSH Terms

Cisplatin*
Drug Therapy
Drug Therapy, Combination*
Humans
Lung Neoplasms*
Lung*
Myalgia
Neutropenia
Paclitaxel*
Peripheral Nervous System Diseases
Survival Rate
Cisplatin
Paclitaxel